6/12/2019 7:03:13 AM
Curis Highlights Publication In Nature Cell Biology Identifying Cancer-Causing Form Of IRAK4 In Patients With AML, MDS
5/14/2019 4:08:10 PM
Curis Q1 Loss/share $0.30 Vs. Loss $0.33 Year Ago
5/6/2019 8:03:18 AM
Curis Completes Mesothelioma Enrollment In CA-170 Study
4/10/2019 8:02:10 AM
Curis Regains Compliance With Nasdaq Continued Listing Requirements
4/5/2019 4:52:50 PM
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
3/26/2019 4:05:45 PM
Curis Q4 Loss/share $0.18 Vs. Loss $0.24 Year Ago
3/25/2019 8:32:49 AM
Curis Sells Portion Of Erivedge Royalties To Oberland Capital For Up To $135.7 Mln
1/24/2019 7:02:32 AM
Curis Says First Mesothelioma Patient Enrolled And Dosed In Phase I Study Of CA-170
11/1/2018 7:04:39 AM
Curis Q3 Net Loss $7.2 Mln Or $0.22/Shr Vs Net Loss $15.5 Mln Or $0.53/Shr Prior Year
10/5/2018 7:01:44 AM
Curis Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)